Mechanism of action of purine analogues in chronic lymphocytic leukaemia.
Pettitt
Andrew R
AR
Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK. andrew.pettitt@rlbuh-tr.nhs.uk
D000970:Antineoplastic Agents / Q000378:metabolism / Q000494:pharmacology*; D017209:Apoptosis; D020169:Caspases / Q000378:metabolism; D002455:Cell Division; D017338:Cladribine / Q000378:metabolism / Q000494:pharmacology*; D004249:DNA Damage; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D015649:Pentostatin / Q000378:metabolism / Q000494:pharmacology*; D010766:Phosphorylation; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*
D000970:Antineoplastic Agents; D016159:Tumor Suppressor Protein p53; D015649:Pentostatin; D017338:Cladribine; D020169:Caspases; D014740:Vidarabine; C024352:fludarabine